GCM
MRNA icon

Gladius Capital Management’s Moderna MRNA Stock Holding History

Gladius Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-162
Closed -$19.7K – 422
2023
Q2 		$19.7K Buy
+162
New +$21.6K ﹤0.01% 305
2022
Q3 		– Sell
-121
Closed -$18K – 453
2022
Q2 		$18K Buy
+121
New +$17.3K ﹤0.01% 321

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Gladius Capital Management's MRNA Position: Q3 2023 in Review

Gladius Capital Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 162 shares — an estimated $19.7K sold.

Gladius Capital Management first reported a position in MRNA in Q2 2022 and held it in 2 quarters. The position peaked at $19.7K in Q2 2023. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Gladius Capital Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 162 Moderna shares in Q3 2023, an estimated $19.7K.
  • Gladius Capital Management first reported a position in Moderna in Q2 2022 and held it in 2 quarters.
  • Gladius Capital Management's Moderna position peaked at $19.7K in Q2 2023.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.